Fusidic acid betamethasone lipid cream.
Bacterial infections of the skin and soft tissues are frequent disorders. They can be primitive infections (e.g. impetigo, folliculitis) or secondary infections complicating other diseases, particularly atopic dermatitis. The most common aetiologic agent is Staphylococcus aureus. Topical antibiotic therapy may be sufficient in many instances to control these infections. Fusidic acid is an antibiotic used topically on the skin which is very active against S. aureus, including methicillin-resistant strains, and other Gram-positive bacteria. Resistance rates to fusidic acid are stably low. A fusidic acid and betamethasone formulation in a lipid-enriched cream (lipid cream) has been recently developed in order to provide effective antibacterial and anti-inflammatory activities in conjunction with a powerful emollient and moisturising effect. This preparation may be especially useful in patients with atopic-infected eczema.
Section of Dermatology, Department of Medicine, University of Verona, Verona, Italy.
G
G
Girolomoni
Department of Biomedical Science for Health, University of Milan, Milan, Italy.
R
R
Mattina
Department of Life Sciences and Biotechnology, School of Pharmacy and Health Products, Master Course in Cosmetic Science and Technologies, University of Ferrara, Ferrara, Italy.
S
S
Manfredini
Department of Life Sciences and Biotechnology, School of Pharmacy and Health Products, Master Course in Cosmetic Science and Technologies, University of Ferrara, Ferrara, Italy.
S
S
Vertuani
Section of Dermatology, Department of Clinical and Experimental Medicine, Parma University, Parma, Italy.
G
G
Fabrizi
D000279:Administration, Cutaneous; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D001623:Betamethasone / Q000008:administration & dosage*; D003876:Dermatitis, Atopic / Q000188:drug therapy; D003879:Dermatologic Agents / Q000008:administration & dosage*; D004338:Drug Combinations; D016503:Drug Delivery Systems; D005672:Fusidic Acid / Q000008:administration & dosage*; D006801:Humans; D009824:Ointments; D012307:Risk Factors; D013207:Staphylococcal Skin Infections / Q000188:drug therapy*; D013211:Staphylococcus aureus
D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D003879:Dermatologic Agents; D004338:Drug Combinations; D009824:Ointments; D005672:Fusidic Acid; D001623:Betamethasone